Filtered By:
Source: Cardiovascular Diabetology

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 81 results found since Jan 2013.

The soluble guanylate cyclase activator cinaciguat prevents cardiac dysfunction in a rat model of type-1 diabetes mellitus
Background: Diabetes mellitus (DM) leads to the development of diabetic cardiomyopathy, which is associated with altered nitric oxide (NO)—soluble guanylate cyclase (sGC)—cyclic guanosine monophosphate (cGMP) signalling. Cardioprotective effects of elevated intracellular cGMP-levels have been described in different heart diseases. In the current study we aimed at investigating the effects of pharmacological activation of sGC in diabetic cardiomyopathy. Methods: Type-1 DM was induced in rats by streptozotocin. Animals were treated either with the sGC activator cinaciguat (10 mg/kg/day) or with placebo orally for 8 wee...
Source: Cardiovascular Diabetology - October 31, 2015 Category: Cardiology Authors: Csaba MátyásBalázs NémethAttila OláhLászló HidiEde BirtalanDalma KellermayerMihály RuppertSevil Korkmaz-IcözGábor KökényEszter HorváthGábor SzabóBéla MerkelyTamás Radovits Source Type: research

Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients
This study aims to evaluate the net effects of metformin monotherapy (MM) on the all-cause mortality and cardiovascular disease (CVD) events. Methods: A retrospective 5-year follow-up cohort study was conducted on Chinese adult patients with T2DM and without any CVD history under public primary care. Cox proportional hazard regressions were performed to compare the risk of all-cause mortality and CVD events (CHD, stroke, heart failure) between patients receiving lifestyle modifications plus MM (MM groups) and those with lifestyle modifications alone (control groups). Results: 3400 pairs of matched patients were compared. M...
Source: Cardiovascular Diabetology - October 9, 2015 Category: Cardiology Authors: Colman FungEric WanCarlos WongFangfang JiaoAnca Chan Source Type: research

HbA1c below 7 % as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis
Conclusions: Relatively tight glucose control has some cardiovascular benefits. HbA1c below 7.0 % as the goal to maximize the cardiovascular benefits remains suspended.
Source: Cardiovascular Diabetology - September 22, 2015 Category: Cardiology Authors: Pin WangRong HuangSen LuWenqing XiaHaixia SunJie SunRongrong CaiShaohua Wang Source Type: research

Association between metabolic syndrome and multiple lesions of intracranial atherothrombotic stroke: a hospital-based study
Conclusion: MetS may be pathophysiologically associated with intracranial atherothrombotic stroke multiplicity in women in particular. Future studies are warranted to confirm the findings.
Source: Cardiovascular Diabetology - August 14, 2015 Category: Cardiology Authors: Kazuhiko KotaniNoriko Satoh-AsaharaTakuya NakakukiHajime YamakageAkira ShimatsuTetsuya Tsukahara Source Type: research

Long-term effects of the multidisciplinary risk assessment and management program for patients with diabetes mellitus (RAMP-DM): a population-based cohort study
This study aimed to evaluate the effectiveness of a multidisciplinary risk assessment and management program for patients with diabetes mellitus (RAMP-DM) in reducing the risks of cardiovascular complications and all-cause mortality. Methods: A prospective cohort study was conducted in 18,188 propensity score matched RAMP-DM participants and subjects with diabetes under usual primary care (9,094 subjects in each group). The study endpoints were the first occurrence of coronary heart disease (CHD), stroke, heart failure (HF), total cardiovascular disease (CVD) and all-cause mortality. We constructed multivariable Cox propor...
Source: Cardiovascular Diabetology - August 14, 2015 Category: Cardiology Authors: Fangfang JiaoColman FungYuk WanSarah McGheeCarlos WongDaisy DaiRuby KwokCindy Lam Source Type: research

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
Background: The cardiovascular (CV) safety of linagliptin was evaluated in subjects with type 2 diabetes (T2DM). Methods: Pre-specified patient-level pooled analysis of all available double-blind, randomized, controlled trials, ≥12 weeks’ duration (19 trials, 9459 subjects) of linagliptin versus placebo/active treatment. Primary end point: composite of prospectively adjudicated CV death, non-fatal myocardial infarction, non-fatal stroke, and hospitalization for unstable angina (4P-MACE). Hospitalization for congestive heart failure (CHF) was also evaluated; adjudication of CHF was introduced during the phase 3 program...
Source: Cardiovascular Diabetology - May 21, 2015 Category: Cardiology Authors: Julio RosenstockNikolaus MarxDietmar NeubacherThomas SeckSanjay PatelHans-Juergen WoerleOdd Johansen Source Type: research

Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors
Conclusions: In patients with type 2 diabetes, management of cardiovascular risk factors and careful monitoring of eGFR may represent opportunities to reduce the risks of death, MI and IS/TIA.
Source: Cardiovascular Diabetology - April 18, 2015 Category: Cardiology Authors: Lucia Cea SorianoSaga JohanssonBergur StefanssonLuis Rodríguez Source Type: research

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
Background: To evaluate the association of treatment with glucagon-like peptide-1 (GLP-1) receptor agonist exenatide and/or insulin on macrovascular outcomes in patients with type 2 diabetes (T2DM). Methods: We conducted a retrospective longitudinal pharmaco-epidemiological study using large ambulatory care data to evaluate the risks of heart failure (HF), myocardial infarction (MI) and stroke in established T2DM patients who received a first prescription of exenatide twice daily (EBID) or insulin between June 2005 and May 2009, with follow-up data available until December 2012. Three treatment groups were: EBID with oral ...
Source: Cardiovascular Diabetology - January 24, 2015 Category: Cardiology Authors: Sanjoy PaulKerenaftali KleinDavid MaggsJennie Best Source Type: research

Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2 diabetes: relation with the glycemic control
Conclusions: In patients with type 2 diabetes, ADMA might be an independent risk factor for long-term adverse cardiovascular events. However, ADMA was not correlated with serum HbA1c level, and in diabetic patients with HbA1c ?6.5%, elevated ADMA level was no longer associated with increased risk of long-term prognosis. Our findings suggested that the prognosis predictive value of ADMA in type 2 diabetes might be modified by the glycemic control.
Source: Cardiovascular Diabetology - December 3, 2014 Category: Cardiology Authors: Chiao-Po HsuPai-Feng HsuMing-Yi ChungShing-Jong LinTse-Min Lu Source Type: research

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in patients with diabetes, who present a 2-4x increased incidence of death from coronary artery disease. Patients with diabetes are considered for cardiovascular disease secondary prevention because their risk level is similar to that reported in patients without diabetes who have already suffered a myocardial infarction. More recently, with a better risk factors control, mainly in intensive LDL cholesterol target...
Source: Cardiovascular Diabetology - October 22, 2014 Category: Cardiology Authors: Francisco SaraivaAndrei Sposito Source Type: research

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
Conclusions: Analysis of pooled data from 20 clinical trials in patients with T2DM suggests that saxagliptin is not associated with an increased CV risk.
Source: Cardiovascular Diabetology - February 4, 2014 Category: Cardiology Authors: Nayyar IqbalArtist ParkerRobert FrederichMark DonovanBoaz Hirshberg Source Type: research

Relationship of obesity and insulin resistance with the cerebrovascular reactivity: a case control study
Conclusions: We found a diminished vasomotor reactivity in individuals with obesity which was not explained by the presence of insulin resistance.
Source: Cardiovascular Diabetology - January 3, 2014 Category: Cardiology Authors: Marcela Rodríguez-FloresCarlos Cantú-BritoEduardo García-GarcíaClaudia Cano-Nigenda Source Type: research

Haemoglobin A1c even within non-diabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama Study
Conclusions: Our findings suggest that elevated HbA1c levels are an independent risk factor for CVD, especially CHD and ischaemic stroke, and that the addition of HbA1c to the model with traditional risk factors significantly improves the predictive ability of CVD.
Source: Cardiovascular Diabetology - November 7, 2013 Category: Cardiology Authors: Fumie IkedaYasufumi DoiToshiharu NinomiyaYoichiro HirakawaNaoko MukaiJun HataKentaro ShikataDaigo YoshidaTakayuki MatsumotoTakanari KitazonoYutaka Kiyohara Source Type: research

Cardiac implications of hypoglycaemia in patients with diabetes -- a systematic review
Conclusions: Emerging data suggest that there is an impact of hypoglycaemia on CV function and mechanistic link is multifactorial. Further research will be needed to ascertain the full impact of hypoglycaemia on the CV system and its complications.
Source: Cardiovascular Diabetology - September 21, 2013 Category: Cardiology Authors: Markolf HanefeldEva DuettingPeter Bramlage Source Type: research

Cardiac implications of hypoglycaemia in patients with diabetes ¿ a systematic review
Conclusions: Emerging data suggest that there is an impact of hypoglycaemia on CV function and mechanistic link is multifactorial. Further research will be needed to ascertain the full impact of hypoglycaemia on the CV system and its complications.
Source: Cardiovascular Diabetology - September 21, 2013 Category: Cardiology Authors: Markolf HanefeldEva DuettingPeter Bramlage Source Type: research